Process validation has undergone a significant transformation in recent years, requiring a reevaluation of our understanding and language surrounding this critical concept. With the FDA’s 2011 guidance, the framework of process validation expanded, emphasizing a continuous lifecycle approach that challenges traditional practices.
The Shift in Definition
The FDA’s revised definition of process validation now encompasses “the collection and evaluation of data, from the process design stage through commercial production.” This change signifies that validation is no longer a finite activity, confined to specific phases or a limited number of batches. Instead, it represents an ongoing commitment to quality throughout the entire lifecycle of a product.
This new perspective necessitates a shift in our vocabulary. Phrases we once relied on, such as “the process was validated,” are now outdated. Acknowledging that validation is perpetual, we must adapt our language to reflect this reality. Today, it’s more accurate to state, “the process was qualified,” highlighting the continuous nature of validation.
Continuous Validation: A Life Cycle Approach
The implication of continuous validation means that every aspect of the manufacturing process is subject to scrutiny and evaluation. Validation is no longer a singular event but an ongoing series of assessments that occur in three stages: development, qualification, and continued verification. As long as a process remains active, it is undergoing some form of validation.
This shift has also affected the terminology associated with validation runs. Rather than being defined by a specific number of batches, every production run can now be considered a validation run, categorized according to its stage of maturity. This evolution underscores a more integrated approach to quality assurance.
Reevaluating Common Terms
As we embrace this new framework, several terms require reevaluation. The notion of “revalidation” is now a misnomer, as it suggests the possibility of redoing something that is inherently continuous. Instead, we might discuss the need for requalification or redevelopment of a process without implying that validation can be undone.
Furthermore, the traditional classifications of validation—retrospective, concurrent, and prospective—have become blurred. The essence of validation now involves ongoing data collection, evaluation, and statistical application, all of which occur simultaneously throughout the process lifecycle.
The Rationale Behind Terminology Choices
One might wonder why the FDA retained the term “process validation,” given its evolved meaning. The choice may stem from the historical significance of the term within the pharmaceutical industry. It serves as a bridge between past practices and contemporary quality assurance methodologies. While alternatives like “process control” or “process stability” could have been more fitting, the retention of “validation” maintains continuity with established regulatory frameworks.
This decision reflects the dual nature of process validation, serving both as a quality assurance tool and a critical component in the regulatory approval of new drugs. The submission of a process validation package to demonstrate manufacturing reliability remains a cornerstone of obtaining marketing authorization.
A Call for Vocabulary Transformation
As we navigate this new landscape, the need for a shift in our quality assurance vocabulary becomes evident. The outdated terminology can create confusion and hinder the adoption of modern practices. By embracing a language that aligns with the continuous nature of process validation, the industry can foster clarity and understanding.
The analogy of “brainwashing” may seem extreme, but a fundamental transformation in mindset is necessary. It is imperative to move away from entrenched notions and embrace a culture of continuous improvement and assurance.
Key Takeaways
- Continuous validation is an ongoing process that spans the entire lifecycle of a product, necessitating a shift in language and understanding.
- Traditional terms like “validation runs” and “revalidation” are outdated and should be replaced with concepts that reflect the current understanding of process validation.
-
The FDA’s decision to retain the term “process validation” maintains continuity with historical practices while adapting to modern quality assurance needs.
-
A vocabulary transformation is crucial for aligning industry practices with contemporary regulatory frameworks, promoting clarity and effective communication.
Conclusion
In conclusion, the evolution of process validation demands a reevaluation of our terminology and practices. By embracing a continuous lifecycle approach and adapting our language accordingly, we can enhance clarity and foster a culture of quality assurance. As the industry moves forward, this shift will be essential in navigating the complexities of modern pharmaceutical manufacturing.
Source: www.pharmtech.com